STOCK TITAN
  1. Home
  2. News
  3. STTK

Shattuck Labs Inc - STTK STOCK NEWS

Welcome to our dedicated news page for Shattuck Labs (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shattuck Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shattuck Labs's position in the market.

News
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients, showing a 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations, and a 27% initial CR with incomplete hematologic recovery (CRi) in frontline TP53m AML patients. SL-172154 demonstrated an acceptable safety and tolerability profile as a monotherapy and in combination with azacitidine. The company will host a conference call and webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
130.33%
Tags
clinical trial
-
News
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) to host investor call on initial data from ongoing clinical trials for cancer and autoimmune disease treatment at the 65th ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.56%
Tags
conferences clinical trial
-
News
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) to participate in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, featuring a fireside chat with Dr. Taylor Schreiber, the company's CEO. The presentation will focus on the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. A live webcast and replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.05%
Tags
none
News
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) reports positive interim data from Phase 1B clinical trials of SL-172154 in treating ovarian cancer and acute myeloid leukemia. The company also provided financial results for Q3 2023, showing cash and cash equivalents of $101.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.21%
Tags
earnings
-
News
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
Rhea-AI Summary
Shattuck Labs, a clinical-stage biotechnology company, will report its third-quarter 2023 financial results and provide a general business overview on November 9, 2023. The earnings call will feature CEO Taylor Schreiber, CFO Andrew Neill, and CMO Lini Pandite. Interested participants can join the webcast or dial in using the provided details. A replay of the webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.05%
Tags
conferences earnings
-
News
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting
Rhea-AI Summary
Shattuck Labs, Inc. announced topline data from the Phase 1 A/B clinical trial of SL-172154 in patients with AML and HR-MDS. The data showed anti-leukemic activity and a tolerable safety profile for SL-172154 as monotherapy and in combination with azacitidine. Response rates were observed in heavily pretreated patients, and early efficacy signals were seen in previously untreated patients with TP53 mutant HR-MDS. The abstract and additional details can be accessed on the ASH Congress portal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
conferences clinical trial
News
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Shattuck Labs, Inc. presented data from Phase 1A clinical trial of SL-172154 in ovarian cancer. Enrollment progressing in Phase 1B trials in AML and PROC. Financial results show cash and investments of $117.2 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
earnings
-
News
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
conferences clinical trial
-
News
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
earnings
News
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
none
Stock STTK logo
Shattuck Labs Inc

Nasdaq:STTK

STTK Rankings

#3012 Ranked by Market Cap
#4347 Ranked by Stock Gains
N/A Ranked by Dividends

STTK Stock Data

443.41M
30.26M
13.26%
59.85%
3.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About STTK

shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex